According to the American Diabetes Association's Standards of Care, GLP-1 RAs with proven cardiovascular benefit, such as semaglutide, may be considered as first-line therapy in patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk, independent of metformin use
Understanding the Side Effects While the combination may be effective, it is important to be aware of the potential for increased side effects
Brew a soothing tea and sip it through the program
Contamination and infection risk represent serious safety concerns when manipulating single-use injection devices
Beyond weight loss, patients often experience improvements in blood pressure, cholesterol levels, and blood sugar control
That's the brand's framing